Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis

Slides:

Advertisements

Similar presentations

Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the.

Advertisements

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D.

Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis Konstantinos A. Toulis, M.D.,

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-stage embryos generated through.

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis Anuja Dokras, M.D., Ph.D., Shari.

Effectiveness and feasibility of hysteroscopic sterilization techniques: a systematic review and meta-analysis Claire F. la Chapelle, M.D., Sebastiaan.

Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,

Akanksha Mehta, M.D., Mark Sigman, M.D. Fertility and Sterility

Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome Elisabeth Lerchbaum,

Outdoor air pollution and sperm quality

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Thyroid antibodies and gestational diabetes mellitus: a meta-analysis

Michael M. Alper, M.D. Fertility and Sterility

Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A

Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials Ana Cobo, Ph.D., César Diaz, M.D.

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study Cem Celik, M.D., Nicel.

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D

Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Iris G. Insogna, M. D. , Malinda S. Lee, M. D. , M. B. A. , Rebecca M

Trends in clinical reproductive medicine research: 10 years of growth

Predictive factors of health-related quality of life in patients with polycystic ovary syndrome: a structural equation modeling approach Fatemeh Bazarganipour,

Reproductive outcomes of testicular versus ejaculated sperm for intracytoplasmic sperm injection among men with high levels of DNA fragmentation in semen:

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: Results of a longitudinal study

Effect of maternal height and weight on risk of preterm birth in singleton and twin births resulting from in vitro fertilization: a retrospective cohort.

Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the.

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis Shiqin Zhu, M.D., Bingqian Zhang, M.D.,

The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial Richard.

Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis Evelien M. Sandberg,

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Ovulation induction in women with polycystic ovary syndrome

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Increased secretion of amylin in women with polycystic ovary syndrome

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Prevalence of polycystic ovary syndrome in adolescents

ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome Lucas Bandeira Marchesan, B.Sc., Poli Mara Spritzer,

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a.

Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation Allison Styne-Gross, M.D., Karen.

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Paolo Moghetti, M.D. Fertility and Sterility

Rupal Shroff, B. S. , Craig H. Syrop, M. D. , William Davis, M. D

Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,

Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions Kristen Farrell, M.S.,

Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration Nicolas.

Current evaluation of amenorrhea

Genetic evaluation procedures at sperm banks in the United States

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Aline Ketefian, M. D. , Jianfang Hu, Ph. D. , Alfred A. Bartolucci, Ph

Clinical and laboratory characteristics of adolescents with both polycystic ovary disease and anorexia nervosa Orit Pinhas-Hamiel, M.D., Nurit Pilpel,

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Nadine M.P. Daan, M.D., Yvonne V.

Infertility induced by cancer treatment: inappropriate or no information provided to majority of French survivors of cancer Julien Mancini, M.D., M.P.H.,

Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test Dimitrios Panidis, M.D., Ph.D., Dimitrios.

Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels

Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis

The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review.

Low body mass index compromises live birth rate in fresh transfer in vitro fertilization cycles: a retrospective study in a Chinese population Jiali.

Presentation transcript:

Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis Daria Lizneva, M.D., Ph.D., Richard Kirubakaran, Ph.D., Kateryna Mykhalchenko, M.D., Larisa Suturina, M.D., Ph.D., Galina Chernukha, M.D., Ph.D., Michael P. Diamond, M.D., Ricardo Azziz, M.D., M.P.H. Fertility and Sterility Volume 106, Issue 6, Pages 1510-1520.e2 (November 2016) DOI: 10.1016/j.fertnstert.2016.07.1121 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Pooled prevalences of the PCOS phenotypes for unselected (n = 9) and referral (n = 34) populations: phenotype A (clinical and/or biochemical HA + OA + PCOM). Referral 50% (95% CI, 46%–54%, I2 = 94.70); unselected 19% (95% CI, 13%–27%, I2 = 87.08); subgroup difference P<.001. Fertility and Sterility 2016 106, 1510-1520.e2DOI: (10.1016/j.fertnstert.2016.07.1121) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Pooled prevalences of the PCOS phenotypes for unselected (n = 9) and referral (n = 34) populations: phenotype B (clinical and/or biochemical HA + OA). Referral 13% (95% CI, 11%–17%, I2 = 96.21); unselected 25% (95% CI, 15%–37%, I2 = 93.25); subgroup difference P=.026. Fertility and Sterility 2016 106, 1510-1520.e2DOI: (10.1016/j.fertnstert.2016.07.1121) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Pooled prevalences of the PCOS phenotypes for unselected (n = 9) and referral (n = 34) populations: phenotype C (clinical and/or biochemical HA + PCOM). Referral 14% (95% CI, 12%–16%, I2 = 91.37); unselected 34% (95% CI, 25%–46%, I2 = 90.75); subgroup difference P<.001. Fertility and Sterility 2016 106, 1510-1520.e2DOI: (10.1016/j.fertnstert.2016.07.1121) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 4 Pooled prevalences of the PCOS phenotypes for unselected (n = 9) and referral (n = 34) populations: phenotype D (OA + PCOM). Referral 17% (95% CI, 13%–22%, I2 = 97.39); unselected 19% (95% CI, 14%–25%, I2 = 78.31); subgroup difference P=.625. Fertility and Sterility 2016 106, 1510-1520.e2DOI: (10.1016/j.fertnstert.2016.07.1121) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Flow chart for systematic review and meta-analysis search methodology. Fertility and Sterility 2016 106, 1510-1520.e2DOI: (10.1016/j.fertnstert.2016.07.1121) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 2 Meta-analysis for the standardized difference in means for BMI in unselected versus referral population. Fertility and Sterility 2016 106, 1510-1520.e2DOI: (10.1016/j.fertnstert.2016.07.1121) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions